Progyny, Inc.
PGNY Healthcare Healthcare Plans
Progyny, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 10.4% from fiscal 2024.
- Revenue
- +8.91%
- EPS
- +115.3%
- Free cash flow
- +2.72%
Quarter to September 2026, against a year earlier
Follow PGNY
Alert me
Progyny, Inc. (PGNY) EV/FCF
As of 6 November 2026, Progyny, Inc. (PGNY) trades at a EV/FCF of 13.7×. Over the past ten years it has ranged from −148× (February 2020) to 397× (April 2022); the current reading is higher than 39% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 9.9× | 36.48% |
| FY2024 | 7.2× | (57.72%) |
| FY2023 | 17.1× | (49.90%) |
| FY2022 | 34.2× | (81.32%) |
| FY2021 | 183× | 82.20% |
| FY2020 | 100× | — |
| FY2019 | −110× | — |
| FY2018 | 16.1× | 0.00% |
| FY2017 | 16.1× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 9.6× | (15.04%) |
| Jun 2026 | 11.3× | 81.13% |
| Mar 2026 | 6.3× | (36.66%) |
| Dec 2025 | 9.9× | 26.49% |
| 28 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| OSCR Oscar Health, Inc. compare | 1.3× |
| CNC Centene Corporation compare | 6.7× |
| CI Cigna Group compare | 12.3× |
| HUM Humana Inc. compare | 12.5× |
| ELV Elevance Health, Inc. compare | 13.1× |
| PGNY Progyny, Inc. | 13.7× |
| ALHC Alignment Healthcare, Inc. compare | 14.4× |
| CLOV Clover Health Investments, Corp. compare | 17.5× |
| MOH Molina Healthcare, Inc compare | 25.4× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on PGNY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement